ATE521367T1 - Flexlibler aufbau- und darreichungs-plattform von impfstoffen - Google Patents
Flexlibler aufbau- und darreichungs-plattform von impfstoffenInfo
- Publication number
- ATE521367T1 ATE521367T1 AT03736977T AT03736977T ATE521367T1 AT E521367 T1 ATE521367 T1 AT E521367T1 AT 03736977 T AT03736977 T AT 03736977T AT 03736977 T AT03736977 T AT 03736977T AT E521367 T1 ATE521367 T1 AT E521367T1
- Authority
- AT
- Austria
- Prior art keywords
- encapsidation
- nucleic acid
- populations
- different
- vlps
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38692102P | 2002-06-07 | 2002-06-07 | |
PCT/US2003/018247 WO2003103605A2 (en) | 2002-06-07 | 2003-06-06 | Flexible vaccine assembly and vaccine delivery platform |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE521367T1 true ATE521367T1 (de) | 2011-09-15 |
Family
ID=29736232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03736977T ATE521367T1 (de) | 2002-06-07 | 2003-06-06 | Flexlibler aufbau- und darreichungs-plattform von impfstoffen |
Country Status (8)
Country | Link |
---|---|
US (2) | US20040033585A1 (de) |
EP (1) | EP1545625B1 (de) |
JP (1) | JP2006507800A (de) |
AT (1) | ATE521367T1 (de) |
AU (1) | AU2003237528A1 (de) |
CA (1) | CA2486118A1 (de) |
WO (1) | WO2003103605A2 (de) |
ZA (1) | ZA200409861B (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7101989B1 (en) * | 1999-07-09 | 2006-09-05 | University Of North Carolina At Chapel Hill | DsrA protein and polynucleotides encoding the same |
US20060121468A1 (en) * | 2002-06-26 | 2006-06-08 | Allnutt F C T | Viruses and virus-like particles for multiple antigen and target display |
CA2547511A1 (en) * | 2003-12-01 | 2005-07-28 | Dow Global Technolgies Inc. | Recombinant icosahedral virus like particle production in pseudomonads |
WO2005108564A2 (en) * | 2004-03-25 | 2005-11-17 | Large Scale Biology Corporation | Production of peptides in plants as viral coat protein fusion |
BRPI0611336A2 (pt) | 2005-06-01 | 2010-08-31 | Dow Global Technologies Inc | método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina |
SG10201502490YA (en) | 2006-09-29 | 2015-05-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
WO2009014782A2 (en) * | 2007-04-27 | 2009-01-29 | Dow Global Technologies Inc. | Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
CN101918028B (zh) | 2007-09-18 | 2015-01-07 | 莱戈赛特医药股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
EP2042193A1 (de) * | 2007-09-28 | 2009-04-01 | Biomay AG | RNA-Impfstoffe |
CN113559253A (zh) * | 2007-11-02 | 2021-10-29 | 约翰霍普金斯大学 | 用于治疗或预防人***瘤病毒感染的多型hpv肽的组合物和方法 |
FR2933194B1 (fr) * | 2008-06-26 | 2010-08-13 | Commissariat Energie Atomique | Procede et dispositif de quantification des contaminants particulaires de surface par analyse amelioree |
US20130224235A1 (en) * | 2008-10-17 | 2013-08-29 | University Of Tartu | Potato virus a coat protein-based vaccines for melanoma |
US20130295131A1 (en) * | 2009-11-05 | 2013-11-07 | Hal S. Padgett | Generation of antigenic virus-like particles through protein-protein linkages |
WO2011130119A2 (en) | 2010-04-14 | 2011-10-20 | Millipore Corporation | Methods of producing high titer, high purity virus stocks and methods of use thereof |
EP3299030B1 (de) | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenterale norovirus-impfstoffformulierungen |
US10117923B2 (en) | 2012-11-07 | 2018-11-06 | Vacplanta Limited | Production of an immunogen using a plant virus |
WO2014074509A1 (en) * | 2012-11-07 | 2014-05-15 | Vacplanta Limted | Production of an immunogen using a plant virus |
MA40824A (fr) | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
EP3341392A4 (de) * | 2015-08-27 | 2019-01-23 | President and Fellows of Harvard College | Zusammensetzungen und verfahren zur schmerzbehandlung |
US11696948B2 (en) | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
BR112020025250A2 (pt) * | 2018-06-12 | 2021-03-09 | Kentucky Bioprocessing, Inc. | Purificação e conjugação de vírus e antígeno |
US11690907B2 (en) | 2018-06-12 | 2023-07-04 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
US11529413B2 (en) | 2018-06-12 | 2022-12-20 | Kbio Holdings Limited | Virus and antigen purification and conjugation |
CN115925972A (zh) | 2019-02-18 | 2023-04-07 | Atb治疗公司 | 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977438A (en) * | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
GB9108386D0 (en) * | 1991-04-19 | 1991-06-05 | Agricultural Genetics Co | Modified plant viruses as vectors |
US5667782A (en) * | 1992-07-16 | 1997-09-16 | Oxford University | Multiple particulate antigen delivery system |
US5443969A (en) * | 1992-10-29 | 1995-08-22 | Rutgers University | RNA packaging system |
JPH08505625A (ja) * | 1993-01-11 | 1996-06-18 | ダナ−ファーバー キャンサー インスティチュート | 細胞毒性tリンパ球応答の誘導 |
WO1995021248A1 (en) * | 1994-02-03 | 1995-08-10 | The Scripps Research Institute | Method for using tobacco mosaic virus to overproduce peptides and proteins |
CA2202761A1 (en) * | 1994-10-18 | 1996-04-25 | Sean Nicholas Chapman | Method of producing a chimeric protein |
US20020032316A1 (en) * | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
US5795754A (en) * | 1995-07-19 | 1998-08-18 | Merck & Co., Inc. | Synthetic HPV11 virus-like particles |
EP0871747A1 (de) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunstimulierung vermittelt durch genmodifizierte dendritische zellen |
FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
US5939262A (en) * | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
US6042820A (en) * | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
ES2572628T3 (es) * | 1997-09-05 | 2016-06-01 | Medimmune, Inc. | Método in vitro para desmontaje/remontaje de partículas análogas al virus del papiloma humano (VLP) |
US7351533B2 (en) * | 1997-09-05 | 2008-04-01 | Medimmune, Inc. | In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents |
US6037456A (en) | 1998-03-10 | 2000-03-14 | Biosource Technologies, Inc. | Process for isolating and purifying viruses, soluble proteins and peptides from plant sources |
KR100292943B1 (ko) * | 1998-03-25 | 2001-09-17 | 윤종용 | 디램장치의제조방법 |
EP1123114B1 (de) * | 1998-10-21 | 2005-12-28 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Virusähnliche partikel zur induktion von autoantikörpern |
US6589529B1 (en) * | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
JP2010510960A (ja) | 1998-11-30 | 2010-04-08 | サイトス バイオテクノロジー アーゲー | 抗原の順序付けられた分子提示、提示の方法、および使用 |
WO2001031046A1 (en) | 1999-10-26 | 2001-05-03 | International Aids Vaccine Initiative | Invasive bacterial vectors for expressing alphavirus replicons |
US6730306B1 (en) | 2000-03-08 | 2004-05-04 | Large Scale Biology Corporation | Parvovirus vaccine as viral coat protein fusions |
AU2001252458A1 (en) * | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
US20020127238A1 (en) | 2000-06-27 | 2002-09-12 | Leonidas Stamatatos | HIV-1 vaccines and screening methods therefor |
DE60234375D1 (de) * | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
-
2003
- 2003-06-06 AU AU2003237528A patent/AU2003237528A1/en not_active Abandoned
- 2003-06-06 CA CA002486118A patent/CA2486118A1/en not_active Abandoned
- 2003-06-06 AT AT03736977T patent/ATE521367T1/de not_active IP Right Cessation
- 2003-06-06 JP JP2004510726A patent/JP2006507800A/ja active Pending
- 2003-06-06 WO PCT/US2003/018247 patent/WO2003103605A2/en active Search and Examination
- 2003-06-06 EP EP03736977A patent/EP1545625B1/de not_active Expired - Lifetime
- 2003-06-06 US US10/457,082 patent/US20040033585A1/en not_active Abandoned
-
2004
- 2004-12-06 ZA ZA200409861A patent/ZA200409861B/en unknown
-
2006
- 2006-04-24 US US11/410,572 patent/US7939318B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ZA200409861B (en) | 2006-07-26 |
WO2003103605A3 (en) | 2005-03-31 |
US20040033585A1 (en) | 2004-02-19 |
US20060188991A1 (en) | 2006-08-24 |
CA2486118A1 (en) | 2003-12-18 |
AU2003237528A1 (en) | 2003-12-22 |
US7939318B2 (en) | 2011-05-10 |
EP1545625B1 (de) | 2011-08-24 |
JP2006507800A (ja) | 2006-03-09 |
EP1545625A2 (de) | 2005-06-29 |
EP1545625A4 (de) | 2008-05-07 |
WO2003103605A2 (en) | 2003-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE521367T1 (de) | Flexlibler aufbau- und darreichungs-plattform von impfstoffen | |
Liu et al. | One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection | |
WO2005091753A3 (en) | Flexible vaccine assembly and vaccine delivery platform | |
ATE437222T1 (de) | Alphavirus replikon-vektorsysteme | |
EE200300331A (et) | Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin | |
NO20025402D0 (no) | Modifiserte ES-celler og ES-spesifikt gen | |
DK1448229T3 (da) | Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr | |
MA33440B1 (fr) | Nouvelles compositions | |
MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
ATE365205T1 (de) | Virale partikel, die nach infektion durch humanes cytomegalovirus freigesetzt werden und ihre verwendung als impfstoff | |
Schmidt et al. | Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development | |
DE60036537D1 (de) | Zusammensetzungen zur gentherapie von diabetes | |
WO2002088328A3 (en) | Method for generating highly active human dendritic cells from monocytes | |
ATE474850T1 (de) | Analoga von peptiden der relaxin-superfamilie | |
WO2004054607A3 (de) | Stabile therapeutische proteine | |
Forsell et al. | Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus | |
DK1321477T3 (da) | Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner | |
ID27206A (id) | Generasi produk-produk perbanyakan gena dari protein-protein fusi simerik melalui pemutusan endoprotease ubikuitus | |
GB2429711A (en) | Heart and skeletal muscle inflammation (HSMI) virus | |
MY162658A (en) | Genes encoding major capsid protein l1 of human papilloma virus and use of the same | |
US20190000994A1 (en) | Method For Inducing Antitumor Immunity Using Sindbis Viral Vectors And Tumor Associated Antigens | |
Liu et al. | Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses | |
Behboudi et al. | Crimean-Congo hemorrhagic fever virus vaccine: past, present, and future | |
EP1578772A4 (de) | Cytokine und cytokinrezeptoren mit reduzierter immunogenität | |
DK1165797T3 (da) | Partikler til genterapi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |